Evolution of Topical NSAIDs in the Guidelines for Treatment of Osteoarthritis in Elderly Patients

Increasing age is the primary predictor of osteoarthritis, the most prevalent painful condition in the US. Because there are no disease-modifying therapies for osteoarthritis, relief of symptoms and maintenance of quality of life through improving joint function become the focus of management. Altho...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Drugs & aging 2012-07, Vol.29 (7), p.523-531
1. Verfasser: Arnstein, Paul M.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 531
container_issue 7
container_start_page 523
container_title Drugs & aging
container_volume 29
creator Arnstein, Paul M.
description Increasing age is the primary predictor of osteoarthritis, the most prevalent painful condition in the US. Because there are no disease-modifying therapies for osteoarthritis, relief of symptoms and maintenance of quality of life through improving joint function become the focus of management. Although highly effective for pain relief, oral nonsteroidal anti-inflammatory drugs (NSAIDs) are associated with systemic adverse reactions that are sometimes treatment limiting, especially for older patients. Thus, osteoarthritis management in elderly populations is shifting away from traditional NSAIDs to therapies that provide comparable pain relief with improved safety. Since the approval by the US Food and Drug Administration of the use of topical NSAIDs to manage osteoarthritis pain, current treatment guidelines put forth by several professional societies have begun to recommend topical NSAIDs as an alternative therapy and, most recently, as first-line therapy for osteoarthritis management in the elderly. This review provides an overview of the various treatment guidelines that are available to assist prescribers in making safe and effective decisions in the treatment of osteoarthritis in this high-risk patient population.
doi_str_mv 10.2165/11631550-000000000-00000
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1021358708</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2692989471</sourcerecordid><originalsourceid>FETCH-LOGICAL-c448t-3f586ac68bc6f5f7d6fa73eabebff3429613584b0680dee4aebf9ec07a6bb9ef3</originalsourceid><addsrcrecordid>eNqFkF9LwzAUxYMo_v8KEhAfq0napM3jmHMORAUn-FbS9kYjXTOTVNi3N7Ob-mZecrj3d-69HIQwJZeMCn5FqUgp5yQh2zeoHXRIaS4TKoXc_dYkYUy-HKAj798jIBij--iAMc4ly7NDpCaftu2DsR22Gs_t0tSqxfdPo9m1x6bD4Q3wtDcNtKYDj7V1eO5AhQV0Ye148AGscuHNmWC-HZO2Adeu8KMKJkL-BO1p1Xo43fzH6PlmMh_fJncP09l4dJfUWVaEJNW8EKoWRVULzXXeCK3yFFQFldZpxqSgKS-yioiCNACZinUJNcmVqCoJOj1G58PcpbMfPfhQvtvedXFlSQlbm3NSRKoYqNpZ7x3ocunMQrlVhMp1tuU22_In20FF69lmQV8toPkxbsOMwMUGUD6mqJ3qauN_OUEKzuR6kBw4H1vdK7i_l_5zxBexR5K7</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1021358708</pqid></control><display><type>article</type><title>Evolution of Topical NSAIDs in the Guidelines for Treatment of Osteoarthritis in Elderly Patients</title><source>MEDLINE</source><source>SpringerNature Journals</source><creator>Arnstein, Paul M.</creator><creatorcontrib>Arnstein, Paul M.</creatorcontrib><description>Increasing age is the primary predictor of osteoarthritis, the most prevalent painful condition in the US. Because there are no disease-modifying therapies for osteoarthritis, relief of symptoms and maintenance of quality of life through improving joint function become the focus of management. Although highly effective for pain relief, oral nonsteroidal anti-inflammatory drugs (NSAIDs) are associated with systemic adverse reactions that are sometimes treatment limiting, especially for older patients. Thus, osteoarthritis management in elderly populations is shifting away from traditional NSAIDs to therapies that provide comparable pain relief with improved safety. Since the approval by the US Food and Drug Administration of the use of topical NSAIDs to manage osteoarthritis pain, current treatment guidelines put forth by several professional societies have begun to recommend topical NSAIDs as an alternative therapy and, most recently, as first-line therapy for osteoarthritis management in the elderly. This review provides an overview of the various treatment guidelines that are available to assist prescribers in making safe and effective decisions in the treatment of osteoarthritis in this high-risk patient population.</description><identifier>ISSN: 1170-229X</identifier><identifier>EISSN: 1179-1969</identifier><identifier>DOI: 10.2165/11631550-000000000-00000</identifier><identifier>PMID: 22559274</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Administration, Topical ; Aged ; Aging ; Analgesics ; Anti-Inflammatory Agents, Non-Steroidal - administration &amp; dosage ; Anti-Inflammatory Agents, Non-Steroidal - adverse effects ; Anti-Inflammatory Agents, Non-Steroidal - therapeutic use ; Arthritis ; Biological and medical sciences ; Blood pressure ; Current Opinion ; Diseases of the osteoarticular system ; Geriatrics/Gerontology ; Humans ; Internal Medicine ; International organizations ; Irritants - administration &amp; dosage ; Irritants - adverse effects ; Irritants - therapeutic use ; Medical sciences ; Medicine ; Medicine &amp; Public Health ; Miscellaneous. Osteoarticular involvement in other diseases ; Motility ; Narcotics ; Nonsteroidal anti-inflammatory drugs ; Older people ; Osteoarthritis ; Osteoarthritis - drug therapy ; Pain ; Patients ; Pharmacology. Drug treatments ; Pharmacology/Toxicology ; Pharmacotherapy ; Physiology ; Practice Guidelines as Topic ; Quality of life ; Society ; Sports injuries</subject><ispartof>Drugs &amp; aging, 2012-07, Vol.29 (7), p.523-531</ispartof><rights>Springer International Publishing AG 2012</rights><rights>2015 INIST-CNRS</rights><rights>Copyright Wolters Kluwer Health Adis International Jul 2012</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c448t-3f586ac68bc6f5f7d6fa73eabebff3429613584b0680dee4aebf9ec07a6bb9ef3</citedby><cites>FETCH-LOGICAL-c448t-3f586ac68bc6f5f7d6fa73eabebff3429613584b0680dee4aebf9ec07a6bb9ef3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.2165/11631550-000000000-00000$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.2165/11631550-000000000-00000$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=26085290$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22559274$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Arnstein, Paul M.</creatorcontrib><title>Evolution of Topical NSAIDs in the Guidelines for Treatment of Osteoarthritis in Elderly Patients</title><title>Drugs &amp; aging</title><addtitle>Drugs Aging</addtitle><addtitle>Drugs Aging</addtitle><description>Increasing age is the primary predictor of osteoarthritis, the most prevalent painful condition in the US. Because there are no disease-modifying therapies for osteoarthritis, relief of symptoms and maintenance of quality of life through improving joint function become the focus of management. Although highly effective for pain relief, oral nonsteroidal anti-inflammatory drugs (NSAIDs) are associated with systemic adverse reactions that are sometimes treatment limiting, especially for older patients. Thus, osteoarthritis management in elderly populations is shifting away from traditional NSAIDs to therapies that provide comparable pain relief with improved safety. Since the approval by the US Food and Drug Administration of the use of topical NSAIDs to manage osteoarthritis pain, current treatment guidelines put forth by several professional societies have begun to recommend topical NSAIDs as an alternative therapy and, most recently, as first-line therapy for osteoarthritis management in the elderly. This review provides an overview of the various treatment guidelines that are available to assist prescribers in making safe and effective decisions in the treatment of osteoarthritis in this high-risk patient population.</description><subject>Administration, Topical</subject><subject>Aged</subject><subject>Aging</subject><subject>Analgesics</subject><subject>Anti-Inflammatory Agents, Non-Steroidal - administration &amp; dosage</subject><subject>Anti-Inflammatory Agents, Non-Steroidal - adverse effects</subject><subject>Anti-Inflammatory Agents, Non-Steroidal - therapeutic use</subject><subject>Arthritis</subject><subject>Biological and medical sciences</subject><subject>Blood pressure</subject><subject>Current Opinion</subject><subject>Diseases of the osteoarticular system</subject><subject>Geriatrics/Gerontology</subject><subject>Humans</subject><subject>Internal Medicine</subject><subject>International organizations</subject><subject>Irritants - administration &amp; dosage</subject><subject>Irritants - adverse effects</subject><subject>Irritants - therapeutic use</subject><subject>Medical sciences</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Miscellaneous. Osteoarticular involvement in other diseases</subject><subject>Motility</subject><subject>Narcotics</subject><subject>Nonsteroidal anti-inflammatory drugs</subject><subject>Older people</subject><subject>Osteoarthritis</subject><subject>Osteoarthritis - drug therapy</subject><subject>Pain</subject><subject>Patients</subject><subject>Pharmacology. Drug treatments</subject><subject>Pharmacology/Toxicology</subject><subject>Pharmacotherapy</subject><subject>Physiology</subject><subject>Practice Guidelines as Topic</subject><subject>Quality of life</subject><subject>Society</subject><subject>Sports injuries</subject><issn>1170-229X</issn><issn>1179-1969</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqFkF9LwzAUxYMo_v8KEhAfq0napM3jmHMORAUn-FbS9kYjXTOTVNi3N7Ob-mZecrj3d-69HIQwJZeMCn5FqUgp5yQh2zeoHXRIaS4TKoXc_dYkYUy-HKAj798jIBij--iAMc4ly7NDpCaftu2DsR22Gs_t0tSqxfdPo9m1x6bD4Q3wtDcNtKYDj7V1eO5AhQV0Ye148AGscuHNmWC-HZO2Adeu8KMKJkL-BO1p1Xo43fzH6PlmMh_fJncP09l4dJfUWVaEJNW8EKoWRVULzXXeCK3yFFQFldZpxqSgKS-yioiCNACZinUJNcmVqCoJOj1G58PcpbMfPfhQvtvedXFlSQlbm3NSRKoYqNpZ7x3ocunMQrlVhMp1tuU22_In20FF69lmQV8toPkxbsOMwMUGUD6mqJ3qauN_OUEKzuR6kBw4H1vdK7i_l_5zxBexR5K7</recordid><startdate>20120701</startdate><enddate>20120701</enddate><creator>Arnstein, Paul M.</creator><general>Springer International Publishing</general><general>Adis International</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>4T-</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope></search><sort><creationdate>20120701</creationdate><title>Evolution of Topical NSAIDs in the Guidelines for Treatment of Osteoarthritis in Elderly Patients</title><author>Arnstein, Paul M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c448t-3f586ac68bc6f5f7d6fa73eabebff3429613584b0680dee4aebf9ec07a6bb9ef3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Administration, Topical</topic><topic>Aged</topic><topic>Aging</topic><topic>Analgesics</topic><topic>Anti-Inflammatory Agents, Non-Steroidal - administration &amp; dosage</topic><topic>Anti-Inflammatory Agents, Non-Steroidal - adverse effects</topic><topic>Anti-Inflammatory Agents, Non-Steroidal - therapeutic use</topic><topic>Arthritis</topic><topic>Biological and medical sciences</topic><topic>Blood pressure</topic><topic>Current Opinion</topic><topic>Diseases of the osteoarticular system</topic><topic>Geriatrics/Gerontology</topic><topic>Humans</topic><topic>Internal Medicine</topic><topic>International organizations</topic><topic>Irritants - administration &amp; dosage</topic><topic>Irritants - adverse effects</topic><topic>Irritants - therapeutic use</topic><topic>Medical sciences</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Miscellaneous. Osteoarticular involvement in other diseases</topic><topic>Motility</topic><topic>Narcotics</topic><topic>Nonsteroidal anti-inflammatory drugs</topic><topic>Older people</topic><topic>Osteoarthritis</topic><topic>Osteoarthritis - drug therapy</topic><topic>Pain</topic><topic>Patients</topic><topic>Pharmacology. Drug treatments</topic><topic>Pharmacology/Toxicology</topic><topic>Pharmacotherapy</topic><topic>Physiology</topic><topic>Practice Guidelines as Topic</topic><topic>Quality of life</topic><topic>Society</topic><topic>Sports injuries</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Arnstein, Paul M.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Docstoc</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><jtitle>Drugs &amp; aging</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Arnstein, Paul M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evolution of Topical NSAIDs in the Guidelines for Treatment of Osteoarthritis in Elderly Patients</atitle><jtitle>Drugs &amp; aging</jtitle><stitle>Drugs Aging</stitle><addtitle>Drugs Aging</addtitle><date>2012-07-01</date><risdate>2012</risdate><volume>29</volume><issue>7</issue><spage>523</spage><epage>531</epage><pages>523-531</pages><issn>1170-229X</issn><eissn>1179-1969</eissn><abstract>Increasing age is the primary predictor of osteoarthritis, the most prevalent painful condition in the US. Because there are no disease-modifying therapies for osteoarthritis, relief of symptoms and maintenance of quality of life through improving joint function become the focus of management. Although highly effective for pain relief, oral nonsteroidal anti-inflammatory drugs (NSAIDs) are associated with systemic adverse reactions that are sometimes treatment limiting, especially for older patients. Thus, osteoarthritis management in elderly populations is shifting away from traditional NSAIDs to therapies that provide comparable pain relief with improved safety. Since the approval by the US Food and Drug Administration of the use of topical NSAIDs to manage osteoarthritis pain, current treatment guidelines put forth by several professional societies have begun to recommend topical NSAIDs as an alternative therapy and, most recently, as first-line therapy for osteoarthritis management in the elderly. This review provides an overview of the various treatment guidelines that are available to assist prescribers in making safe and effective decisions in the treatment of osteoarthritis in this high-risk patient population.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>22559274</pmid><doi>10.2165/11631550-000000000-00000</doi><tpages>9</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1170-229X
ispartof Drugs & aging, 2012-07, Vol.29 (7), p.523-531
issn 1170-229X
1179-1969
language eng
recordid cdi_proquest_journals_1021358708
source MEDLINE; SpringerNature Journals
subjects Administration, Topical
Aged
Aging
Analgesics
Anti-Inflammatory Agents, Non-Steroidal - administration & dosage
Anti-Inflammatory Agents, Non-Steroidal - adverse effects
Anti-Inflammatory Agents, Non-Steroidal - therapeutic use
Arthritis
Biological and medical sciences
Blood pressure
Current Opinion
Diseases of the osteoarticular system
Geriatrics/Gerontology
Humans
Internal Medicine
International organizations
Irritants - administration & dosage
Irritants - adverse effects
Irritants - therapeutic use
Medical sciences
Medicine
Medicine & Public Health
Miscellaneous. Osteoarticular involvement in other diseases
Motility
Narcotics
Nonsteroidal anti-inflammatory drugs
Older people
Osteoarthritis
Osteoarthritis - drug therapy
Pain
Patients
Pharmacology. Drug treatments
Pharmacology/Toxicology
Pharmacotherapy
Physiology
Practice Guidelines as Topic
Quality of life
Society
Sports injuries
title Evolution of Topical NSAIDs in the Guidelines for Treatment of Osteoarthritis in Elderly Patients
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-18T17%3A42%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evolution%20of%20Topical%20NSAIDs%20in%20the%20Guidelines%20for%20Treatment%20of%20Osteoarthritis%20in%20Elderly%20Patients&rft.jtitle=Drugs%20&%20aging&rft.au=Arnstein,%20Paul%20M.&rft.date=2012-07-01&rft.volume=29&rft.issue=7&rft.spage=523&rft.epage=531&rft.pages=523-531&rft.issn=1170-229X&rft.eissn=1179-1969&rft_id=info:doi/10.2165/11631550-000000000-00000&rft_dat=%3Cproquest_cross%3E2692989471%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1021358708&rft_id=info:pmid/22559274&rfr_iscdi=true